Yesterday afternoon, Adamis (ADMP) announced FDA approval of its lower dose version (0.15mg) of Symjepi for treatment of anaphylaxis in pediatric patients.
Adamis Pharmaceuticals (NASDAQ:ADMP) shares tumbled as much as 30% this month, prompting plenty of inquiries from investors. Dr.
It’s a big day for Adamis Pharma (NASDAQ:ADMP). The drug maker announced a commercial partnership for its generic EpiPe Symjepi with Novartis (NYSE:NVS) subsidiary Sandoz, …
Adamis Pharmaceuticals (NASDAQ:ADMP) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 45% upturn. …
Adamis Pharmaceuticals Corp (NASDAQ:ADMP) shares are shooting up 34% faster than Jack’s magic bean sparking right into a giant beanstalk. The reason?
With the tremendous focus on the opioid crisis, Raymond James’ Elliot Wilbur sees exciting potential for Adamis.
Adamis Pharmaceuticals Corp (NASDAQ:ADMP) announced the submission of an Investigational New Drug (IND) application to the U.S.
Now that ADMP has submitted a PAS for its pediatric version of Symjepi, an epipnephrine injection cheaper than Mylan’s EpiPen, FBR’s Andrew D’silva sees a potential approval with less risk than the original version.
Adamis Stock Can Reach $13 as Symjepi Deal Is Imminent
Celsion Withdraws Stock Offering Celsion Corporation (NASDAQ:CLSN) shares are on a massive upswing, climbing nearly 110% in pre-market trading Friday on the heels of the …